Skip to main content
. 2017 Jul 19;8(35):58847–58864. doi: 10.18632/oncotarget.19375

Figure 6. CIP2A overexpression confers lapatinib resistance in breast cancer cells.

Figure 6

(A) Survival fraction of BT474 and BT474/LR cells after lapatinib treatment for 5 days was examined by an MTS assay. All values are presented as the mean ± S.E. (B) RTK and CIP2A expression and/or activity levels in BT474 and BT474/LR cells treated with lapatinib for 24 hours were detected by Western blotting.